Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
November 27 2023 - 7:00AM
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,
diversified specialty pharmaceutical company, today announced that
the U.S. Court of Appeals for the Federal Circuit has upheld the
judgment of the Patent Trial and Appeal Board (PTAB) in its final
decision that Purdue’s ‘961 patent, which Purdue has claimed is
infringed by Xtampza® ER, is invalid.
The Federal Circuit’s decision affirming the
invalidity of Purdue’s ‘961 patent confirms both that the PTAB had
statutory authority to issue its final decision, and that the PTAB
did correctly conclude that the ʼ961 patent was invalid.
“We applaud the Federal Circuit’s decision to
confirm the authority of the PTAB and uphold its finding of
invalidity of Purdue’s patent,” said Shirley Kuhlmann, Chief
Administrative Officer and General Counsel of Collegium. “We will
continue to vigorously defend Collegium's intellectual property
against claims of infringement.”
About Collegium Pharmaceutical,
Inc.
Collegium is a leading, diversified specialty
pharmaceutical company committed to improving the lives of people
living with serious medical conditions. Collegium’s headquarters
are located in Stoughton, Massachusetts. For more information,
please visit the Company’s website
at www.collegiumpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. We may, in some cases, use terms such as
"believes," "potential," "expects," "plans," "intends," "may,"
"could," "might," "should" or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Examples of forward-looking statements contained in
this press release include, among others, statements related to our
expectations relating to the timing and outcome of patent
litigation. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results, performance, or achievements to differ materially from the
company’s current expectations. Actual results may differ
materially from management’s expectations and such forward-looking
statements in this press release could be affected as a result of
various important factors, including risks relating to, among
others, the outcome of any current or future patent infringement
litigation that may be brought by or against us. These and other
risks are described under the heading "Risk Factors" in our Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q and other
filings with the SEC. Any forward-looking statements that we
make in this press release speak only as of the date of this press
release. We assume no obligation to update our forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Investor Contact:Christopher
James, M.D.
Vice
President, Investor Relationsir@collegiumpharma.com
Media Contact:Marissa
SamuelsVice President, Corporate
Communicationscommunications@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2024 to May 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From May 2023 to May 2024